NCT05045248

Efficacy of Apraclonidine Eye Drops in the Treatment of Ptosis Secondary to Myasthenia Gravis

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 10 (actual)
• Sponsor: American University of Beirut Medical Center · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study is aimed at assessing the efficacy of Apraclonidine eye drops in the treatment of ptosis secondary to myasthenia gravis.

Detailed description

The rationale behind using Apraclonidine is that it acts on Muller's muscle which is a sympathetic-innervated muscle. As such, this muscle is expected to be spared from the effects of the autoantibodies that attack the postsynaptic portion of the neuromuscular junction in myasthenia gravis.

Conditions

• Myasthenia Gravis
• Ocular Myasthenia Gravis

Interventions

Type	Name	Description
DRUG	Apraclonidine Hcl 0.5% Oph Soln	Each patient is administered 2 drops of Apraclonidine 0.5% solution to the most affected eye

Timeline

• Start date: 2020-06-01
• Primary completion: 2021-04-15
• Completion: 2021-04-15
• First posted: 2021-09-16
• Last updated: 2021-09-16

Locations

1 site across 1 country: Lebanon

Regulatory

• FDA-regulated drug study